Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
NEW HAVEN, Conn., July 27, 2026 /PRNewswire/ -- Biohaven Ltd.
Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®) Early clinical activity observed: Phase 1 dose-escalation data show
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk
08:17am, Monday, 13'th Jul 2026
Biohaven's pipeline is now more focused after having to narrow down its R&D efforts to other assets. Today, I think opakalim's pivotal epilepsy readout is probably the most important near-term catalys
Biohaven Announces Scientific Leadership Transitions
05:00pm, Thursday, 09'th Jul 2026
David Pirman, Ph.D. promoted to Executive Vice President and Head of Discovery Bruce Car, Ph.D.
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
07:30am, Tuesday, 30'th Jun 2026
Enrollment complete in pivotal Phase 2/3 study evaluating opakalim in focal epilepsy (RISE3); top-line results on track for 2H 2026 Emerging opakalim focal epilepsy and idiopathic generalized epilepsy
Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
02:04pm, Monday, 29'th Jun 2026
Biohaven Ltd. (NYSE:BHVN) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday's Pre-Market Session
08:11am, Monday, 29'th Jun 2026
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday.
BHV-1300 is the first MoDE™ extracellular protein degrader to enter a pivotal trial, pioneering a new class of precision immunology medicines that eliminate the disease-driving antibodies at the roo
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
03:28pm, Thursday, 18'th Jun 2026
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-13
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
07:30am, Monday, 01'st Jun 2026
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir
Biohaven: Despite Today's Gains, I Remain Skeptical
03:12pm, Wednesday, 27'th May 2026
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs. BHVN - spun out of the original Biohaven after its acquisition by Pfizer - a
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TS
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakali
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 05'th May 2026
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
04:02pm, Monday, 04'th May 2026
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Piv
